| scholarly article | Q13442814 |
| P50 | author | Ryan R. Morrison | Q88743376 |
| Anna Louise Blobaum | Q88790203 | ||
| Darren W. Engers | Q88790205 | ||
| Carrie K Jones | Q88790208 | ||
| Kimberly Italiano | Q114738662 | ||
| Jacob Bode | Q114738663 | ||
| Corey R. Hopkins | Q41522772 | ||
| Marianne Amalric | Q55436887 | ||
| Michael Bubser | Q60323558 | ||
| Colleen M. Niswender | Q67215380 | ||
| Craig W. Lindsley | Q67215429 | ||
| P. Jeffrey Conn | Q67215432 | ||
| P2093 | author name string | J Scott Daniels | |
| Analisa D Thompson | |||
| Jonathan W Dickerson | |||
| Thomas M Bridges | |||
| Satyawan Jadhav | |||
| Nathalie Turle-Lorenzo | |||
| P2860 | cites work | Parkinson's disease: clinical features and diagnosis | Q22242021 |
| Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. | Q24647634 | ||
| Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs) | Q24650602 | ||
| Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment | Q24655595 | ||
| Metabotropic glutamate receptors in the basal ganglia motor circuit | Q28280931 | ||
| Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS | Q28569174 | ||
| Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum | Q30306766 | ||
| Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry | Q30975753 | ||
| An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point | Q33347238 | ||
| (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. | Q34271753 | ||
| Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease | Q34639873 | ||
| Current pharmacotherapeutic treatment options in Parkinson's disease | Q36857140 | ||
| Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia | Q37095863 | ||
| Adenosine A2A receptors and Parkinson's disease. | Q37565218 | ||
| Glutamate receptors as therapeutic targets for Parkinson's disease | Q37585401 | ||
| Metabotropic glutamate receptors: physiology, pharmacology, and disease | Q37670222 | ||
| Combination Analysis | Q37782346 | ||
| Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. | Q39838136 | ||
| Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy | Q40026195 | ||
| Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists | Q40113390 | ||
| Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia | Q40958986 | ||
| Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. | Q42445750 | ||
| A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function | Q42463405 | ||
| Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial | Q42751053 | ||
| Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders | Q42959494 | ||
| A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug | Q43232822 | ||
| Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus | Q44658747 | ||
| Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons | Q46370920 | ||
| Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. | Q46485167 | ||
| The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates | Q46506816 | ||
| Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission | Q46986845 | ||
| The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. | Q48442446 | ||
| Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography. | Q48482084 | ||
| Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. | Q48667702 | ||
| Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse. | Q48690811 | ||
| Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: Quantification using the rotational model | Q67010898 | ||
| Modification of dopamine and norepinephrine metabolism in the rat brain by monoamine oxidase inhibitors | Q69426180 | ||
| Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat | Q71884054 | ||
| CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury | Q73503153 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 404-421 | |
| P577 | publication date | 2011-11-16 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease | |
| P478 | volume | 340 |
| Q38200930 | Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued |
| Q34068934 | Adenosinergic regulation of striatal clock gene expression and ethanol intake during constant light |
| Q38139547 | Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders |
| Q38155480 | Animal models of Parkinson's disease: a gateway to therapeutics? |
| Q27305419 | Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents |
| Q34534818 | Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers |
| Q40435465 | Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type |
| Q34373958 | Development of allosteric modulators of GPCRs for treatment of CNS disorders |
| Q42409715 | Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4). |
| Q42271745 | Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). |
| Q42145142 | Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy |
| Q92490629 | Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease |
| Q34522043 | Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4). |
| Q39085798 | Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4. |
| Q39378056 | Functional selectivity induced by mGlu₄ receptor positive allosteric modulation and concomitant activation of Gq coupled receptors |
| Q35124773 | Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease |
| Q38242117 | Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential |
| Q30402875 | Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7 |
| Q38002888 | Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature |
| Q41818450 | Metabotropic glutamate receptors for Parkinson's disease therapy |
| Q34468639 | Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation |
| Q26995351 | Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease |
| Q34399823 | Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders |
| Q38056875 | Overcoming obstacles in Parkinson's disease |
| Q35738538 | Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist |
| Q37183072 | Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors |
| Q38209092 | Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications |
| Q37999106 | Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders |
| Q48112379 | Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia |
| Q64232180 | Selectivity of Dietary Phenolics for Inhibition of Human Monoamine Oxidases A and B |
| Q30432649 | Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction |
| Q89814598 | Synthesis and Characterization of Fluorine-18-Labeled N-(4-Chloro-3-((fluoromethyl-d2)thio)phenyl)picolinamide for Imaging of mGluR4 in Brain |
| Q30643015 | Systemic inflammation regulates microglial responses to tissue damage in vivo |
| Q38056852 | Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease |
| Q36844773 | The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia |
| Q36203237 | The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. |
| Q38190016 | Therapeutic potential of targeting glutamate receptors in Parkinson's disease. |
| Q38092819 | Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease |
| Q30821694 | mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome |
| Q38660240 | mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias |
| Q40035243 | mGluR4-containing corticostriatal terminals: synaptic interactions with direct and indirect pathway neurons in mice |
Search more.